Oncology Today with Dr Neil Love HER2-Positive Gastrointestinal Cancers — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
6 snips
Mar 19, 2026 Dr Zev Wainberg, UCLA medical oncologist focused on gastroesophageal cancer; Prof Eric Van Cutsem, Leuven academic oncologist with European trial expertise; Dr Haley Ellis, MGH oncologist experienced in biliary tract HER2 disease. They discuss TIGIT and immunotherapy skepticism, sequencing and salvage HER2 strategies, rebiopsy and ctDNA after progression, CNS metastasis management, neoadjuvant HER2 approaches, and toxicity monitoring.
AI Snips
Chapters
Transcript
Episode notes
TIGIT Combinations Face High Bar For Benefit
- TIGIT combinations face an uphill battle in gastric and biliary cancers due to multiple recent negative trials.
- Speakers referenced STAR221 and other failures, noting adjuvant ARTEMIDE results will be crucial but showing skepticism about large survival gains.
Target HER2 In Second-Line Biliary Tract Cancer
- Target HER2 when present because non-biomarker second-line options in biliary tract cancer are inadequate.
- Haley Ellis recommends chemo-free zanidatamab or T-DXd given strong second-line efficacy and durable responses like 15 months.
Watch After Resected Isolated Brain Metastasis
- Do not automatically give additional systemic anti-HER2 therapy after isolated, resected brain metastasis treated with surgery and radiation.
- Zev Wainberg advises observation off therapy for isolated, fully treated CNS relapse.